Q-omics provides the consensus-scored CCDC127 profile across patient tissues and cancer cell-line models. CCDC127 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC127 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CCDC127 protein abundance shows 21,566 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where CCDC127 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC127 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC127 survival associations across molecular data types. CCDC127 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC127 RNA expression–survival associations across cancer types. High CCDC127 expression shows unfavorable associations in UVM, LIHC, KIRP, COAD and STAD, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC127 RNA expression.
This table summarizes CCDC127 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC127. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC127 shows higher tumor expression in KIRC, HNSC, LUAD, LIHC, KIRP and LUSC. The KIRC box plot shows higher CCDC127 RNA expression in tumor versus normal tissue (log2 FC = +1.298, t-test p < 0.001).
This table shows molecular features associated with CCDC127 in patient tissues and cancer cell lines. In patient samples, CCDC127 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC127 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
